Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Arcus Biosciences, Inc.    RCUS

ARCUS BIOSCIENCES, INC.

(RCUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Arcus Biosciences Shares Rise 11% on AstraZeneca Partnership

10/29/2020 | 12:22pm EST

By Chris Wack

Arcus Biosciences Inc. shares were up 11% at $22.67 after the company said it was in a collaboration with AstraZeneca to evaluate domvanalimab in combination with Imfinzi durvalumab in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer.

AstraZeneca's Imfinzi is the only immunotherapy approved for patients with unresectable Stage III NSCLC. Results from a Phase 3 trial showed treatment with Imfinzi following chemotherapy and radiation therapy led to unprecedented survival in unresectable Stage III NSCLC, with an estimated 50% of patients surviving four years versus 36% for CRT alone, and 35% of patients not progressing after four years versus 20% for CRT alone.

Arcus is currently evaluating domvanalimab in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic NSCLC evaluating zimberelimab monotherapy, versus domvanalimab with zimberelimab, versus domvanalimab plus etrumadenant with zimberelimab.

Under the terms of the agreement, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply its respective anti-cancer agent to support the trial. The companies will share costs for the trial.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

10-29-20 1321ET

Stocks mentioned in the article
ChangeLast1st jan.
ARCUS ASA 0.92% 44.3 Delayed Quote.19.73%
ARCUS BIOSCIENCES, INC. -3.94% 24.37 Delayed Quote.141.29%
ASTRAZENECA PLC -0.45% 7690 Delayed Quote.1.85%
All news about ARCUS BIOSCIENCES, INC.
11/18ARCUS BIOSCIENCES : to Participate in the Evercore ISI 3rd Annual HealthCONx Vir..
BU
11/12ARCUS BIOSCIENCES : Investor Presentation October 2020
PU
11/11ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
AQ
11/10ARCUS BIOSCIENCES : Announces New Employment Inducement Grants
BU
11/06ARCUS BIOSCIENCES : Announces Third Quarter 2020 Financial Results and Corporate..
AQ
11/05ARCUS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
11/05ARCUS BIOSCIENCES, INC. : Results of Operations and Financial Condition, Financi..
AQ
11/05ARCUS BIOSCIENCES : Announces Third Quarter 2020 Financial Results and Corporate..
BU
10/29Arcus Biosciences Shares Rise 11% on AstraZeneca Partnership
DJ
10/29ARCUS BIOSCIENCES : to Collaborate With AstraZeneca on Registrational Trial for ..
BU
More news
Financials (USD)
Sales 2020 75,9 M - -
Net income 2020 -114 M - -
Net cash 2020 498 M - -
P/E ratio 2020 -11,8x
Yield 2020 -
Capitalization 1 582 M 1 582 M -
EV / Sales 2020 14,3x
EV / Sales 2021 29,6x
Nbr of Employees 139
Free-Float 68,1%
Chart ARCUS BIOSCIENCES, INC.
Duration : Period :
Arcus Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARCUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 39,00 $
Last Close Price 24,37 $
Spread / Highest target 105%
Spread / Average Target 60,0%
Spread / Lowest Target 6,69%
EPS Revisions
Managers
NameTitle
Terry J. Rosen Chairman & Chief Executive Officer
Juan Carlos Jaen President & Director
Jennifer Jarrett Chief Operating Officer & Director
Robert C. Goeltz Chief Financial & Accounting Officer
Steve Young Senior VP-Technology & Quantitative Biology
Sector and Competitors
1st jan.Capitalization (M$)
ARCUS BIOSCIENCES, INC.141.29%1 582
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555